Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis

Roberto Petrioli; Giandomenico Roviello; Laura Zanotti; Franco Roviello; Karol Polom; Alberto Bottini; Luigi Marano; Edoardo Francini; Daniele Marrelli; Daniele Generali

doi:10.1016/j.critrevonc.2016.04.001

Back

Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis

Journal article

Peer reviewed

Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis

Roberto Petrioli, Giandomenico Roviello, Laura Zanotti, Franco Roviello, Karol Polom, Alberto Bottini, Luigi Marano, Edoardo Francini, Daniele Marrelli and Daniele Generali

Critical reviews in oncology/hematology, Vol.102, pp.82-88

06/01/2016

DOI: 10.1016/j.critrevonc.2016.04.001

PMID: 27083592

View Online

Abstract

Docetaxel or Epirubicin-based regimens are both approved for the treatment of metastatic gastric cancer. We perform a systemic review with metanalysis to evaluate the efficacy and toxicities of docetaxel-based chemotherapy compared with epirubicin-containing regimens. A metaanalysis of randomized studies in accordance with the preference guidelines for reported items in systematic reviews and meta-analyses is performed in which the databases of PubMed, the Cochrane Library, and the ASCO University Meeting were searched for relevant publications. The primary outcome was efficacy, the secondary toxicities. A total of 553 cases were included in the meta-analysis; 278 received epirubicin-based treatment and 313 received docetaxel. The pooled risk ratio to achieve an objective response and a disease control rate were 1.08 (95% CI 0.85–1.37; P=0.52) and 0.90 (95% CI 0.75–1.08; P=0.27) respectively. EPI arm showed a decrease in the risk of neutropenia, anemia, fatigue, asthenia and diarrhea, paraesthesia; docetaxel arm showed a decrease in the risk of leucopenia, thrombocytopenia, anorexia, nausea, nausea-vomiting, stomatitis and neutropenic fever. The results of our study suggest a similar activity of docetaxel and epirubicin-based chemotherapeutic regimens in metastatic gastric cancer. Other parameters as, comorbidity, concomitant diseases and prior therapies should be taken into account to address the clinician's choice in selecting the best therapeutical approach for any single patient.

Chemotherapy

Docetaxel

Epirubicin

Gastric cancer

Details

Title: Subtitle: Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis
Creators: Roberto Petrioli - University of Siena
Giandomenico Roviello - Istituti Ospitalieri di Cremona
Laura Zanotti - Istituti Ospitalieri di Cremona
Franco Roviello - University of Siena
Karol Polom
Alberto Bottini - Istituti Ospitalieri di Cremona
Luigi Marano - Ospedale di Spoleto
Edoardo Francini - Policlinico Umberto I
Daniele Marrelli - University of Trieste
Daniele Generali - University of Siena
Resource Type: Journal article
Publication Details: Critical reviews in oncology/hematology, Vol.102, pp.82-88
DOI: 10.1016/j.critrevonc.2016.04.001
PMID: 27083592
NLM abbreviation: Crit Rev Oncol Hematol
ISSN: 1040-8428
eISSN: 1879-0461
Publisher: Elsevier Ireland Ltd
Number of pages: 7
Language: English
Date published: 06/01/2016
Academic Unit: Internal Medicine
Record Identifier: 9985221243002771

Metrics

2 Record Views

34 Times Cited - Web of Science